Estimaciones de analistas de Wall Street para Stryker Corporation (SYK): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 1 |
| Compra | 37 |
| Mantener | 14 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 52 |
| Calificación media (1-5) | 0.75 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-10-29 | $3.62 | ||
| 2026-07-30 | $3.69 | $3.49 | +5.7% |
| 2026-04-30 | $2.60 | $2.98 | -12.8% |
| 2026-01-29 | $4.47 | $4.40 | +1.6% |
| 2025-10-30 | $3.19 | $3.13 | +1.9% |
| 2025-07-31 | $3.13 | $3.07 | +2.0% |
| 2025-05-01 | $2.84 | $2.71 | +4.8% |
| 2025-01-28 | $4.01 | $3.87 | +3.6% |
Ratios de valoración
| Ratio P/E | 27.82 |
| Precio / Valor contable | 4.33 |
| EV / EBITDA | 19.02 |
| Rentabilidad por dividendo | 1.29% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $11.32B | $12.44B | $13.60B | $14.88B | $14.35B | $17.11B | $18.45B | $20.50B | $22.59B | $25.12B |
| Coste de Ventas | $4.08B | $4.54B | $5.00B | $5.50B | $5.60B | $6.40B | $7.41B | $8.00B | $8.62B | $9.05B |
| Beneficio Bruto | $7.25B | $7.90B | $8.60B | $9.38B | $8.75B | $10.71B | $11.04B | $12.49B | $13.98B | $16.07B |
| I+D | $715.0M | $787.0M | $862.0M | $971.0M | $905.0M | $1.13B | $1.23B | $1.29B | $1.41B | $1.58B |
| Generales y Administrativos | $3.95B | $4.35B | $4.63B | $5.02B | $4.82B | $5.81B | $6.08B | $6.92B | $7.50B | $8.65B |
| Gastos Operativos | $4.67B | $5.14B | $5.50B | $5.99B | $5.72B | $6.95B | $7.31B | $8.21B | $8.92B | $11.18B |
| Beneficio Operativo | $2.58B | $2.77B | $3.10B | $3.39B | $3.03B | $3.76B | $3.73B | $4.28B | $5.06B | $4.89B |
| EBITDA | $2.69B | $2.95B | $3.34B | $3.63B | $3.08B | $3.61B | $4.02B | $5.06B | $4.94B | $6.31B |
| Gastos por Intereses | $228.0M | $247.0M | $264.0M | $287.0M | $315.0M | $337.0M | $337.0M | $356.0M | $396.0M | $607.0M |
| Beneficio Antes de Impuestos | $1.92B | $2.06B | $2.36B | $2.56B | $1.95B | $2.28B | $2.68B | $3.67B | $3.49B | $4.51B |
| Impuestos | $274.0M | $1.04B | -$1.20B | $479.0M | $355.0M | $287.0M | $325.0M | $508.0M | $499.0M | $1.27B |
| Beneficio Neto | $1.65B | $1.02B | $3.55B | $2.08B | $1.60B | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B |
| BPA | $4.40 | $2.73 | $9.50 | $5.57 | $4.26 | $5.29 | $6.23 | $8.34 | $7.86 | $8.49 |
| BPA Diluido | $4.35 | $2.68 | $9.34 | $5.48 | $4.20 | $5.22 | $6.17 | $8.25 | $7.76 | $8.40 |
| Acciones en Circulación (Diluidas) | $378.5M | $380.1M | $380.3M | $379.9M | $380.3M | $382.3M | $382.2M | $383.7M | $385.6M | $382.2M |
Precio
| Precio | $275.12 |
| Capitalización | $105.5B |
| Bolsa | NYSE |
| País | US |
Empresas relacionadas: AMGN · BSX · DHR · GILD · HCA · MCK · MDT
Explorar sector: Healthcare · Medical - Devices
Más secciones de SYK: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones